|  Help  |  About  |  Contact Us

Publication : Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways.

First Author  Wojtas AM Year  2017
Journal  Proc Natl Acad Sci U S A Volume  114
Issue  33 Pages  E6962-E6971
PubMed ID  28701379 Mgi Jnum  J:244424
Mgi Id  MGI:5913203 Doi  10.1073/pnas.1701137114
Citation  Wojtas AM, et al. (2017) Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. Proc Natl Acad Sci U S A 114(33):E6962-E6971
abstractText  Alzheimer's disease (AD) is characterized by amyloid-beta (Abeta) peptide deposition in brain parenchyma as plaques and in cerebral blood vessels as cerebral amyloid angiopathy (CAA). CAA deposition leads to several clinical complications, including intracerebral hemorrhage. The underlying molecular mechanisms that regulate plaque and CAA deposition in the vast majority of sporadic AD patients remain unclear. The clusterin (CLU) gene is genetically associated with AD and CLU has been shown to alter aggregation, toxicity, and blood-brain barrier transport of Abeta, suggesting it might play a key role in regulating the balance between Abeta deposition and clearance in both brain and blood vessels. Here, we investigated the effect of CLU on Abeta pathology using the amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of AD amyloidosis on a Clu+/+ or Clu-/- background. We found a marked decrease in plaque deposition in the brain parenchyma but an equally striking increase in CAA within the cerebrovasculature of APP/PS1;Clu-/- mice. Surprisingly, despite the several-fold increase in CAA levels, APP/PS1;Clu-/- mice had significantly less hemorrhage and inflammation. Mice lacking CLU had impaired clearance of Abeta in vivo and exogenously added CLU significantly prevented Abeta binding to isolated vessels ex vivo. These findings suggest that in the absence of CLU, Abeta clearance shifts to perivascular drainage pathways, resulting in fewer parenchymal plaques but more CAA because of loss of CLU chaperone activity, complicating the potential therapeutic targeting of CLU for AD.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

7 Bio Entities

Trail: Publication

0 Expression